210 related articles for article (PubMed ID: 10929035)
1. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
Hjertner O; Qvigstad G; Hjorth-Hansen H; Seidel C; Woodliff J; Epstein J; Waage A; Sundan A; Börset M
Br J Haematol; 2000 Jun; 109(4):815-22. PubMed ID: 10929035
[TBL] [Abstract][Full Text] [Related]
2. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
3. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
Luparello C; Del Rosso M
Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
[TBL] [Abstract][Full Text] [Related]
4. Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
He C; He P; Liu LP; Zhu YS
J Cancer Res Clin Oncol; 2001; 127(3):180-6. PubMed ID: 11260863
[TBL] [Abstract][Full Text] [Related]
5. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
6. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies.
Floridon C; Nielsen O; Holund B; Sunde L; Westergaard JG; Thomsen SG; Teisner B
Placenta; 1999 Nov; 20(8):711-21. PubMed ID: 10527826
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
Longstaff C; Merton RE; Fabregas P; Felez J
Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
11. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Busso N; Péclat V; So A; Sappino AP
Ann Rheum Dis; 1997 Sep; 56(9):550-7. PubMed ID: 9370880
[TBL] [Abstract][Full Text] [Related]
13. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
14. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
16. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
[TBL] [Abstract][Full Text] [Related]
17. Regulation and role of urokinase plasminogen activator in vascular remodelling.
Tkachuk V; Stepanova V; Little PJ; Bobik A
Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
[TBL] [Abstract][Full Text] [Related]
18. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
19. Urokinase induces receptor mediated brain tumor cell migration and invasion.
MacDonald TJ; DeClerck YA; Laug WE
J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
[TBL] [Abstract][Full Text] [Related]
20. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
